4.7 Article

STAMP2 increases oxidative stress and is critical for prostate cancer

期刊

EMBO MOLECULAR MEDICINE
卷 7, 期 3, 页码 315-331

出版社

WILEY
DOI: 10.15252/emmm.201404181

关键词

activating transcription factor 4; iron reductase; prostate cancer; reactive oxygen species; six transmembrane protein of prostate 2

资金

  1. Norwegian Research Council [193337, 1917331]
  2. Norwegian Cancer Society [419204]
  3. Anders Jahre Fund

向作者/读者索取更多资源

The six transmembrane protein of prostate 2 (STAMP2) is an androgen-regulated gene whose mRNA expression is increased in prostate cancer (PCa). Here, we show that STAMP2 protein expression is increased in human PCa compared with benign prostate that is also correlated with tumor grade and treatment response. We also show that STAMP2 significantly increased reactive oxygen species (ROS) in PCa cells through its iron reductase activity which also depleted NADPH levels. Knockdown of STAMP2 expression in PCa cells inhibited proliferation, colony formation, and anchorage-independent growth, and significantly increased apoptosis. Furthermore, STAMP2 effects were, at least in part, mediated by activating transcription factor 4 (ATF4), whose expression is regulated by ROS. Consistent with in vitro findings, silencing STAMP2 significantly inhibited PCa xenograft growth in mice. Finally, therapeutic silencing of STAMP2 by systemically administered nanoliposomal siRNA profoundly inhibited tumor growth in two established preclinical PCa models in mice. These data suggest that STAMP2 is required for PCa progression and thus may serve as a novel therapeutic target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Gan Wang, Min Zhang, Ping Meng, Chengbo Long, Xiaodong Luo, Xingwei Yang, Yunfei Wang, Zhiye Zhang, James Mwangi, Peter Muiruri Kamau, Zhi Dai, Zunfu Ke, Yi Zhang, Wenlin Chen, Xudong Zhao, Fei Ge, Qiumin Lv, Mingqiang Rong, Dongsheng Li, Yang Jin, Xia Sheng, Ren Lai

Summary: Unlike healthy cells, cancer cells heavily rely on the molecular chaperone protein TRiC, particularly its subunit CCT4, for protein folding and maintenance of proteostasis. In this study, we demonstrate that targeting CCT4 with the compound anticarin-beta can effectively inhibit osteosarcoma cell survival and impede STAT3 maturation. Anticarin-beta shows high selectivity for cancer cells and exhibits remarkable antitumor efficacy in orthotopic and patient-derived xenograft models of osteosarcoma.

ACTA PHARMACEUTICA SINICA B (2022)

Article Gastroenterology & Hepatology

Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

Marta Alonso-Nocelo, Laura Ruiz-Canas, Patricia Sancho, Kivanc Gorgulu, Sonia Alcala, Coral Pedrero, Mireia Vallespinos, Juan Carlos Lopez-Gil, Marina Ochando, Elena Garcia-Garcia, Sara Maria David Trabulo, Paola Martinelli, Patricia Sanchez-Tomero, Carmen Sanchez-Palomo, Patricia Gonzalez-Santamaria, Lourdes Yuste, Sonja Maria Wormann, Derya Kabacaoglu, Julie Earl, Alberto Martin, Fernando Salvador, Sandra Valle, Laura Martin-Hijano, Alfredo Carrato, Mert Erkan, Laura Garcia-Bermejo, Patrick C. Hermann, Hana Algul, Gema Moreno-Bueno, Christopher Heeschen, Francisco Portillo, Amparo Cano, Bruno Sainz

Summary: LOXL2 plays an important role in pancreatic ductal adenocarcinoma (PDAC), with its loss inhibiting metastasis and prolonging overall survival, while overexpression promotes tumor growth and decreases overall survival. Macrophage-secreted OSM is an inducer of LOXL2 expression, with targeting macrophages affecting its expression and collagen fiber alignment.
Article Multidisciplinary Sciences

AXL inhibition improves BRAF-targeted treatment in melanoma

Marta Nyakas, Karianne Giller Fleten, Mads Haugland Haugen, Nikolai Engedal, Christina Sveen, Inger Nina Farstad, Vivi Ann Florenes, Lina Prasmickaite, Gunhild Mari Maelandsmo, Kotryna Seip

Summary: This study investigated the therapeutic potential of combining an AXL inhibitor (AXLi) and a clinically relevant BRAF inhibitor (BRAFi) for the treatment of metastatic melanoma. The results showed that AXL was expressed in the majority of melanoma lymph node metastases. In vitro experiments demonstrated that the combination of AXLi and BRAFi resulted in the largest reduction in cell viability. Moreover, pre-clinical studies using AXL(high) melanoma models showed a therapeutic benefit of adding AXLi to the BRAF-targeted therapy. Mechanistic insights revealed that AXLi potentiated BRAFi-induced apoptosis, stimulated ferroptosis, and inhibited autophagy. Overall, this study suggests that combining AXLi with standard therapy could improve the therapeutic outcome in metastatic melanoma.

SCIENTIFIC REPORTS (2022)

Article Chemistry, Multidisciplinary

Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer

Rourou Xiao, Lixin You, Li Zhang, Xichen Guo, Ensong Guo, Faming Zhao, Bin Yang, Xi Li, Yu Fu, Funian Lu, Zizhuo Wang, Chen Liu, Wenju Peng, Wenting Li, Xiaohang Yang, Yingyu Dou, Jingbo Liu, Wei Wang, Tianyu Qin, Yaoyuan Cui, Xiaoxiao Zhang, Fuxia Li, Yang Jin, Qingping Zeng, Beibei Wang, Gordon B. Mills, Gang Chen, Xia Sheng, Chaoyang Sun

Summary: The WEE1 inhibitor AZD1775 induces endoplasmic reticulum stress and activates the PERK and IRE1 alpha branches of the unfolded protein response in TP53 mutant ovarian cancer models. Inhibition of the IRE1 alpha-XBP1s pathway may enhance the efficacy of AZD1775.

ADVANCED SCIENCE (2022)

Article Oncology

A novel prognostic signature in osteosarcoma characterised from the perspective of unfolded protein response

Chengcheng Shi, Faming Zhao, Tingting Zhang, Denghui Xu, Zhuangyu Hao, Fengzhen Cui, Ji-Hua Shi, Yang Jin, Ningning Li, Caihong Yang, Yi Zhang, Xia Sheng

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

Article Cell Biology

Gremlin-1 Promotes Colorectal Cancer Cell Metastasis by Activating ATF6 and Inhibiting ATF4 Pathways

Ruohan Li, Huaixiang Zhou, Mingzhe Li, Qiuyan Mai, Zhang Fu, Youheng Jiang, Changxue Li, Yunfei Gao, Yunping Fan, Kaiming Wu, Clive Da Costa, Xia Sheng, Yulong He, Ningning Li

Summary: This study found that GREM1 protein promotes invasion and metastasis of colorectal cancer cells by regulating the expression of ATF6 and ATF4, possibly through the modulation of PI3K/AKT/mTOR and BMP2 signaling pathways.
Article Oncology

Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer

Yixin Jin, Kristina Berg Lorvik, Yang Jin, Carole Beck, Adam Sike, Irene Persiconi, Emilie Kvaloy, Fahri Saatcioglu, Claire Dunn, Jon Amund Kyte

Summary: This study describes a CAR T cell targeting STEAP1 and demonstrates its potential clinical application in prostate cancer. The CAR T cells showed specific response against STEAP1 and effectively inhibited tumor growth and prolonged survival in vivo.

MOLECULAR THERAPY-ONCOLYTICS (2022)

Article Environmental Sciences

Association of exposure to per- and polyfluoroalkyl substances with hemoglobin and hematocrit during pregnancy

Fengzhen Cui, Hongxiu Liu, Yuanyuan Li, Tong-Zhang Zheng, Shunqing Xu, Wei Xia, Xia Sheng

Summary: The study found a positive association between maternal exposure to PFASs and serum Hb and HCT levels. Furthermore, iron supplementation during pregnancy may influence this relationship.

ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY (2022)

Letter Oncology

Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunotherapy

Okan Safak, Shenghan Wang, Carmen Mota Reyes, Ibrahim Halil Guercinar, Sergey Tokalov, Nedim Can Cevik, Kivanc Goerguelue, Bengi Su Yilmaz, Emre Erdogan, Linhan Ye, Qiaolin Li, Elif Arik Sever, Samed Oezer, Gueldal Sueyen, Helmut Friess, Gueralp Onur Ceyhan, Rouzanna Istvanffy, Hana Alguel, Ihsan Ekin Demir

CANCER COMMUNICATIONS (2023)

Article Oncology

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Vigdis Nygaard, Anne Hansen Ree, Vegar Johansen Dagenborg, Anne-Lise Borresen-Dale, Bjorn Edwin, Asmund Avdem Fretland, Krzysztof Grzyb, Mads H. Haugen, Gunhild M. Maelandsmo, Kjersti Flatmark

Summary: A mesenchymal subgroup with an immunosuppressive phenotype, characterized by high expression of immune checkpoints HAVCR2/TIM-3 and VISTA, as well as the M2 macrophage marker CD163, was identified in colorectal cancer liver metastases. These findings suggest potential novel opportunities for immune-based therapy approaches in microsatellite stable colorectal cancer.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Oncology

ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series

Margherita Ambrosini, Marzia Del Re, Paolo Manca, Andrew Hendifar, Alexander Drilon, Guilherme Harada, Anne Hansen Ree, Samuel Klempner, Gunhild Mari Maelandsmo, Kjersti Flatmark, Hege G. Russnes, James M. Cleary, Harshabad Singh, Elisa Sottotetti, Antonia Martinetti, Giovanni Randon, Andrea Sartore-Bianchi, Iolanda Capone, Massimo Milione, Maria Di Bartolomeo, Filippo Pietrantonio

Summary: This study collected data from patients with GI cancers and ALK rearrangements, showing remarkable responses and clinical benefit with ALK inhibitors. Despite the low frequency, ALK rearrangements play an important role in personalized treatment for GI cancers.

JCO PRECISION ONCOLOGY (2022)

Article Oncology

STAMP2 suppresses autophagy in prostate cancer cells by modulating the integrated stress response pathway

Jorgen Sikkeland, Matthew Yoke Wui Ng, Hatice Zeynep Nenseth, Bilal Unal, Su Qu, Yang Jin, Anne Simonsen, Fahri Saatcioglu

Summary: STAMP2 suppresses autophagy through modulation of the integrated stress response axis and regulates mitochondrial respiration, both of which have significant metabolic effects and support PCa growth.

AMERICAN JOURNAL OF CANCER RESEARCH (2022)

暂无数据